Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure
Source: View publication →
In this randomized, open-label trial, prophylactic implantable cardioverter-defibrillator (ICD) implantation in patients with symptomatic nonischemic systolic heart failure did not significantly reduce the rate of all-cause mortality compared with usual clinical care.
Key Findings
Study Design
Study Limitations
Clinical Significance
The DANISH trial challenged the routine recommendation for primary prevention ICDs in all patients with nonischemic cardiomyopathy, highlighting that modern medical therapy and CRT have likely altered the risk-benefit profile, necessitating a more personalized approach to patient selection.
Historical Context
Prior to the DANISH trial, ICD indications for nonischemic cardiomyopathy were largely extrapolated from trials involving ischemic heart disease or mixed populations (such as SCD-HeFT). DANISH was the first large-scale, contemporary, randomized trial to specifically investigate the survival benefit of primary prevention ICDs in a dedicated cohort of patients with symptomatic nonischemic heart failure.
Guided Discussion
High-yield insights from every perspective
The DANISH trial observed that while sudden cardiac death was significantly reduced by the ICD, all-cause mortality was not. What is the pathophysiological explanation for why preventing a specific cause of death (arrhythmia) might not translate into a survival benefit in patients with nonischemic cardiomyopathy compared to those with ischemic cardiomyopathy?
Key Response
In nonischemic cardiomyopathy, patients are more likely to die from progressive pump failure (heart failure) or non-cardiac comorbidities rather than the ventricular arrhythmias common in ischemic heart disease (scar-mediated re-entry). The 'competing risk' of death from non-arrhythmic causes is higher in this population, meaning that even if the ICD successfully terminates a lethal rhythm, the underlying disease process or other conditions often claim the patient shortly thereafter.
A 72-year-old male with nonischemic cardiomyopathy and an LVEF of 30% asks if he should receive an ICD. Based on the subgroup analysis of the DANISH trial, how does patient age modify the expected benefit of prophylactic ICD implantation in this population?
Key Response
The DANISH trial found a significant interaction between age and the benefit of an ICD. Patients younger than 68 years experienced a significant reduction in all-cause mortality (HR 0.64), whereas older patients (≥68 years) saw no survival benefit. For a resident, this highlights the importance of clinical reasoning: in older patients, the competing risks of death from pump failure or age-related comorbidities outweigh the protection offered by an ICD against sudden cardiac death.
In the DANISH trial, approximately 58% of patients in both arms were treated with Cardiac Resynchronization Therapy (CRT). How does the inclusion of CRT-Pacemaker (CRT-P) and CRT-Defibrillator (CRT-D) patients potentially dilute the observed treatment effect of the ICD in a trial of nonischemic heart failure?
Key Response
CRT itself promotes reverse remodeling, improves LVEF, and reduces both heart failure and sudden cardiac death. By including a large population receiving CRT, the 'baseline' mortality in the control group is lowered, and the substrate for arrhythmia may be reduced. This makes it significantly harder to demonstrate an incremental survival benefit of an ICD (CRT-D vs. CRT-P) on top of modern guideline-directed medical therapy and resynchronization.
Given the DANISH results, should we move toward a 'selective' rather than 'blanket' application of primary prevention ICDs in nonischemic patients, and what parameters beyond LVEF should now be prioritized in the shared decision-making process?
Key Response
The trial forces a shift from LVEF-only criteria to a more nuanced risk stratification. Attendings should teach that age, the presence/extent of myocardial fibrosis on Cardiac MRI (Late Gadolinium Enhancement), and the patient's overall frailty are more predictive of benefit than EF alone. In NICM, an ICD is less a 'default' and more a discussion about the 'mode of death'—preventing a quick death in a patient who might otherwise have many productive years ahead.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The DANISH trial utilized a traditional Cox proportional-hazards model for its primary analysis. Critique the use of this model in the presence of 'competing risks' (e.g., death from progressive heart failure vs. sudden cardiac death) and how a Fine-Gray subdistribution hazard model might have altered the interpretation of the device's efficacy.
Key Response
In device trials, competing risks are critical. If a patient dies of pump failure, they can no longer experience sudden cardiac death. The Cox model can overestimate the absolute risk of the event of interest in these scenarios. A Fine-Gray model would more accurately account for these competing events, likely further emphasizing that the absolute benefit of an ICD in the nonischemic population is smaller than previously estimated due to the high incidence of non-arrhythmic mortality.
The DANISH trial was an open-label study where clinicians were aware of which patients had an ICD. As a reviewer, what are the primary threats to internal validity regarding 'performance bias' and 'ascertainment bias' in this trial, and how might they have influenced the null result?
Key Response
A reviewer would flag that clinicians might have managed patients in the control group more aggressively (closer follow-up, more frequent medication titration) because they lacked the 'safety net' of an ICD (performance bias). Additionally, the determination of 'sudden cardiac death' is notoriously subjective; knowledge of the presence of a device could influence how a physician adjudicates the cause of death (ascertainment bias), though all-cause mortality remains a robust, objective endpoint.
How do the results of the DANISH trial reconcile the discrepancy between the 2021 ESC Guidelines and the 2022 AHA/ACC/HFSA Guidelines regarding the strength of recommendation for primary prevention ICDs in nonischemic cardiomyopathy?
Key Response
The DANISH trial prompted the ESC to downgrade the recommendation for ICDs in nonischemic cardiomyopathy from Class I to Class IIa. Conversely, the 2022 AHA/ACC/HFSA guidelines maintained a Class I recommendation (Level of Evidence: A), citing meta-analyses that include older trials (like DEFINITE) which suggest a benefit. The committee must decide if one high-quality, modern trial (DANISH) should override older evidence that was gathered before the widespread use of ARNI, SGLT2i, and CRT.
Clinical Landscape
Noteworthy Related Trials
MADIT-II Trial
Tested
Prophylactic ICD implantation
Population
Patients with a prior myocardial infarction and an LVEF of 30% or less
Comparator
Conventional medical therapy
Endpoint
All-cause mortality
COMPANION Trial
Tested
Cardiac resynchronization therapy (CRT) with or without ICD
Population
Patients with NYHA class III or IV heart failure and a prolonged QRS interval
Comparator
Optimal pharmacological therapy alone
Endpoint
All-cause mortality or hospitalization for heart failure
SCD-HeFT Trial
Tested
Implantable cardioverter-defibrillator (ICD)
Population
Patients with New York Heart Association class II or III heart failure and an LVEF of 35% or less
Comparator
Placebo or Amiodarone
Endpoint
All-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis